Endpoints for Clinical Trials Evaluating Disease Modification and Structural Damage in Adults with Crohn's Disease

被引：85

作者：

D'Haens, Geert R. ^{[1
]}

Fedorak, Richard ^{[2
]}

Lemann, Marc ^{[3
]}

Feagan, Brian G. ^{[4
]}

Kamm, Michael A. ^{[5
]}

Cosnes, Jacques ^{[6
]}

Rutgeerts, Paul J. ^{[7
]}

Marteau, Philippe ^{[8
]}

Travis, Simon ^{[9
]}

Schoelmerich, Juergen ^{[10
]}

Hanauer, Steven ^{[11
]}

Sandborn, William J. ^{[12
]}

机构：

[1] Imelda GI Clin Res Ctr, B-2820 Bonheiden, Belgium

[2] Univ Alberta, Edmonton, AB T6G 2M7, Canada

[3] Hop St Louis, Paris, France

[4] Robarts Clin Trials Ctr, London, ON, Canada

[5] Univ Melbourne, St Vincents Hosp, Melbourne, Vic 3010, Australia

[6] Hop St Antoine, F-75571 Paris, France

[7] Katholieke Univ Leuven, Louvain, Belgium

[8] Lariboisiere Hosp, Paris, France

[9] Radcliffe Infirm, Oxford OX2 6HE, England

[10] Univ Regensburg, Regensburg, Germany

[11] Univ Chicago Hosp, Chicago, IL 60637 USA

[12] Mayo Clin, Rochester, MN USA

来源：

INFLAMMATORY BOWEL DISEASES | 2009年 / 15卷 / 10期

关键词：

endpoints; clinical trials; disease modification; structural damage; Crohn's disease; INFLAMMATORY-BOWEL-DISEASE; MAINTENANCE TREATMENT; EPISODIC TREATMENT; NOD2/CARD15; GENE; INFLIXIMAB; RESECTION; PATTERN; RISK; CLASSIFICATION; BEHAVIOR;

D O I：

10.1002/ibd.21034

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The management of Crohn's disease is rapidly changing. The advent of potent immunomodulatory and biologic therapies has led to more demanding endpoints for clinical trials than only clinical response and remission. Complete withdrawal of corticosteroids, healing of endoscopically visible lesions, and prevention of structural damage are only a few new endpoints that are finding their way into the clinical trials of today and those that are being developed for the future. Given the importance of selecting the most appropriate and relevant endpoints, the International Organization for Inflammatory Bowel Diseases (IOIBD) decided to develop guidelines that could be used by individual researchers, the pharmaceutical industry, and the regulatory bodies. The Current document is to be read as a "position paper," which is the result of several years of discussion and consensus finding that was finally approved by the entire membership of the group. The proposed instruments will need further validation and standardization to demonstrate that they are reliable in stable disease and responsive to change, and to determine the cutoff points for response and remission.

引用

页码：1599 / 1604

页数：6

共 50 条

[1] Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease [J].